8-K current report · filed Nov 13, 2026

Tonix Pharmaceuticals Holding Corp. (TNXP) 8-K Current Report: November 13, 2026

Item 8.01TNXP overview

Short answer

Tonix Pharmaceuticals Holding Corp. (TNXP) filed an 8-K current report with the SEC on November 13, 2026 reporting Item 8.01 (Other Events). DRL filed a Paragraph IV ANDA challenging four Orange Book patents covering TONMYA 2.8 mg.

Tonix Pharmaceuticals Holding Corp. 8-K event analysis

AI summary of each reported item and its exhibits

Item 8.01 · Other Events

  • DRL filed a Paragraph IV ANDA challenging four Orange Book patents covering TONMYA 2.8 mg
  • Tonix sued DRL for patent infringement in New Jersey on November 13, 2026
  • Lawsuit triggers up to 30-month statutory stay of final FDA approval for DRL’s generic
  • Patent litigation protects TONMYA exclusivity temporarily but creates legal costs and generic-competition risk
  • Adverse patent ruling could accelerate generic entry and pressure TONMYA sales

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Tonix Pharmaceuticals Holding Corp. 8-K filings

Get the next TNXP 8-K as it lands

Follow TNXP for push alerts, or ask the research agent what this filing means.